Phase III Study Comparing Weekly Dose-Dense Chemotherapy to Standard Treatment in Women With Poor Prognosis Ovarian Cancer After Incomplete Surgery
Led by ARCAGY/ GINECO GROUP · Updated on 2026-08-04
250
Participants Needed
76
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new chemotherapy dosing approach in women with poor prognostic ovarian cancers who have unfavorable primary chemosensitivity and incomplete debulking surgery. This phase III trial compares a salvage weekly dose-dense chemotherapy regimen to continuing the standard chemotherapy regimen, aiming to confirm if adjusting the dose and schedule improves outcomes. The study is pragmatic and open-label, reflecting routine clinical practice in a real-world patient population.
Participants are randomly assigned to one of two groups an experimental arm receiving a intensified chemotherapy schedule with carboplatin and paclitaxel given weekly in 3-week cycles for three cycles, optionally combined with daily subcutaneous GCSF injections or a standard arm continuing the same 3-weekly carboplatin-paclitaxel regimen used during initial treatment, with optional GCSF support. Randomization accounts for factors like bevacizumab use, BRCA mutation status, and KELIM score subgroup. The treatment period focuses on this chemotherapy phase.
During the trial, participants will be monitored for surgery outcomes, overall and progression-free survival, tumor response, and adverse events. Assessments include clinical evaluations and imaging based on RECIST criteria, with follow-up extending up to five years for survival analysis. Researchers will also evaluate the impact of additional treatments like PARP inhibitors and bevacizumab on patient outcomes. The total study duration covers treatment and long-term monitoring of efficacy and safety measures.
CONDITIONS
Brief Title
Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery
Research Team
M
Marine COGNAT
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Not eligible for complete interval debulking surgery due to incomplete surgery attempt or disease considered inoperable
ECOG performance status 0 or 1
Adequate organ and bone marrow function for weekly chemotherapy
Adequate liver and kidney function as specified
Provided written informed consent
Affiliated to a social insurance regime
Willing and able to comply with study protocol and visits
You will not qualify if you...
Low-grade or mixed histology types including endometrioid, clear cell, mucinous, sarcomatous, or borderline ovarian tumors
Contraindication to carboplatin, paclitaxel, or GCSF
Previous bevacizumab treatment during initial neo-adjuvant chemotherapy
Primary platinum-refractory disease with progression during initial chemotherapy
Concomitant cancers except certain treated skin, cervical, or solid tumors with no disease for 5 years or more
Participation in other investigational drug trials during randomized chemotherapy phase
Uncontrolled significant medical conditions such as unstable angina, recent myocardial infarction, severe arrhythmia, heart failure, cirrhosis, active infections requiring IV therapy, gastric or small bowel obstruction
Known psychiatric disorders affecting compliance
Pregnant or breastfeeding, or planning pregnancy during study
Legal restrictions such as being under guardianship or deprived of liberty
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 3 cycles of 3-week treatment
Participants receive either the salvage weekly dose-dense chemotherapy regimen or continue the standard 3-weekly carboplatin-paclitaxel chemotherapy.
Follow-up
Duration - Up to 5 years
Participants are monitored for surgery outcomes, tumor response, progression-free and overall survival, and adverse events for up to 5 years.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of 177LuBetaBart Monoclonal Antibody for Safety and Early Effects in Adults With Advanced Solid Tumors
Evaluation of 18FFAPI-74 PET Imaging Compared to Standard Methods for Detecting Multiple Cancer Types
Evaluating 18F-T2 PETCT Imaging for Detecting Tumors with High CAIX Levels in Adults
Exploratory Study of 68Ga-SorB PETCT Imaging to Diagnose Sortilin-Positive Solid Tumors
Study of Preventive Surgery Options for Women with High Genetic Risk of Hereditary Ovarian Cancer
Observing Effects on Cancer Risk, Ovarian Function, and Quality of Life
Study Comparing the Pharmacokinetics and Safety of BR2022 and BR2022-1
in Female Patients with BRCA-Mutated Advanced Ovarian Cancer
Using Olaparib Treatment
Phase 1 Study of CD70-targeted CAR-T Cells for Advanced or Metastatic CD70-positive Gynecologic Cancer
Phase I Study of CD70-targeted CAR-T Therapy for Adults with Advanced or Metastatic CD70-positive Solid Tumors
Open Multicenter Study of SHR-A1811 Combined With Chemotherapy for Treating Platinum Sensitive Recurrent Ovarian Cancer
Phase II Study of SYS6041 Combination Therapy Evaluating Safety and Efficacy in Recurrent Ovarian Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
SALVOVAR: a pragmatic randomized phase III trial comparing the SALVage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic OVARian cancers.